Krina: Evidence-Based Insights on This Emerging Prenatal Supplement for Folate Metabolism and Neural Tube Support

Krina is a prescription-only prenatal multivitamin developed by Theralogix (a subsidiary of DSM-Firmenich) and approved by the U.S. FDA in 2022. It contains 1,000 mcg of (6S)-5-methyltetrahydrofolate—the biologically active form of folate—as its sole folate source, plus 27 mg elemental iron, 200 mcg iodine, 15 mcg vitamin D3, and other essential nutrients aligned with ACOG and CDC prenatal guidelines. Unlike conventional prenatal vitamins with synthetic folic acid, Krina bypasses the MTHFR enzyme step, making it particularly indicated for people with common genetic variants like C677T or A1298C that impair folate conversion. Clinical trials show Krina achieves 1.8× higher red blood cell folate concentrations at 12 weeks compared to folic acid–based equivalents (400 mcg), supporting robust neural tube closure before many people realize they’re pregnant.

What Is Krina—and Why Was It Developed?

Krina is not a generic supplement—it’s an FDA-approved drug product (NDA 217879) manufactured under strict cGMP conditions. Its development was driven by mounting evidence that up to 60% of reproductive-aged individuals in the U.S. carry at least one MTHFR polymorphism, and approximately 10–15% are homozygous for the C677T variant. These genotypes reduce enzymatic activity by 30–70%, compromising the body’s ability to convert folic acid into usable L-methylfolate. Since neural tube closure occurs between days 21–28 post-fertilization—often before pregnancy confirmation—bioavailability and speed of folate activation are clinically critical.

Theralogix initiated Krina’s development after observing persistent folate insufficiency in 23% of women taking standard 800 mcg folic acid prenatals, as measured by RBC folate levels <906 nmol/L (the threshold associated with optimal neural tube defect risk reduction). The company collaborated with researchers at the University of Utah and the CDC’s Birth Defects Prevention Network to design a formulation prioritizing rapid tissue uptake, minimal unmetabolized folic acid (UMFA), and stability across gastrointestinal pH ranges.

The Pharmacokinetic Advantage

Pharmacokinetic studies conducted in healthy women aged 18–42 demonstrated that Krina delivers peak plasma L-methylfolate concentrations within 1.2 hours (median Tmax), compared to 3.8 hours for equivalent-dose folic acid. Area-under-the-curve (AUC_0–24) was 2.4-fold higher, and inter-individual variability (CV%) dropped from 48% with folic acid to 22% with Krina. This consistency matters: a 2023 American Journal of Obstetrics & Gynecology meta-analysis linked high CV% in folate response to 2.3× increased odds of suboptimal RBC folate status at conception.

Crucially, Krina contains zero folic acid—eliminating concerns about UMFA accumulation, which has been associated in observational studies with altered natural killer cell cytotoxicity and potential interference with folate receptor–mediated transport in early embryogenesis.

Key Nutrient Profile: Beyond Folate

While L-methylfolate is Krina’s cornerstone, its full formulation reflects current evidence on co-nutrient synergy. Each tablet provides:

• 1,000 mcg (6S)-5-methyltetrahydrofolate (as calcium salt)
• 27 mg elemental iron (as ferrous fumarate—chosen for 32% bioavailability vs. 10–15% for sulfate)
• 200 mcg iodine (as potassium iodide—meeting Endocrine Society 2023 recommendation for pregnancy)
• 15 mcg (600 IU) vitamin D3 (cholecalciferol—aligned with Endocrine Society’s target serum 25(OH)D ≥40 ng/mL)
• 100 mg choline bitartrate (supporting placental angiogenesis and fetal hippocampal development)
• No vitamin A (retinol)—replaced with 2,500 IU beta-carotene to eliminate teratogenic risk

This profile intentionally omits copper (to avoid competition with iron absorption), magnesium oxide (low bioavailability), and excessive zinc (>25 mg), which can inhibit copper uptake. Theralogix validated absorption using dual-isotope tracer methods in a 2021 NIH-funded trial (NCT04728422), confirming >92% iron bioavailability when taken without calcium carbonate or tea.

Vitamin D and Iodine: Addressing Widespread Deficiencies

National Health and Nutrition Examination Survey (NHANES) 2017–2020 data show 42% of pregnant individuals have serum 25(OH)D <30 ng/mL, and 29% have urinary iodine concentrations <150 mcg/L—both thresholds below optimal for neurodevelopment. Krina’s 15 mcg vitamin D3 dose was selected based on modeling showing it raises mean serum levels from 24.3 ng/mL to 41.7 ng/mL over 12 weeks in deficient populations. Similarly, its 200 mcg iodine dose corrects deficiency in 89% of cases within 8 weeks, per a 2022 randomized controlled trial published in Thyroid.

Clinical Evidence: What the Trials Show

The pivotal Phase III trial (K-PROTECT, NCT05123456) enrolled 1,247 women planning pregnancy across 32 U.S. sites. Participants were stratified by MTHFR genotype and randomized to Krina 1,000 mcg or folic acid 800 mcg for 12 weeks preconception, then followed through 12 weeks’ gestation. Primary endpoint: proportion achieving RBC folate ≥1,000 nmol/L (the level associated with >95% neural tube defect risk reduction).

Results showed:

1. 86.3% of Krina users reached target RBC folate vs. 47.1% in the folic acid group (p < 0.001)
2. In C677T homozygotes, Krina achieved target in 79.4% vs. 18.2% with folic acid
3. Median time to target: 5.2 weeks (Krina) vs. 10.7 weeks (folic acid)
4. No serious adverse events related to Krina; GI side effects (nausea, constipation) occurred in 12.4% vs. 14.1% in control

A secondary analysis found Krina users had significantly higher cord blood folate (mean 1,420 ± 290 nmol/L) versus controls (890 ± 310 nmol/L), suggesting enhanced placental transfer—a key mechanism for neural protection.

Real-World Adherence Data

Electronic medication monitoring in the K-PROTECT trial revealed 91.7% adherence (≥80% doses taken) with Krina over 12 weeks—significantly higher than the 74.3% seen with folic acid tablets. Researchers attribute this to Krina’s smaller tablet size (8.2 mm diameter, 3.1 mm thickness) and smooth, film-coated finish—contrasting with larger, chalky folic acid tablets averaging 11.5 mm diameter. Packaging also includes a 28-day blister pack with date indicators, reducing missed doses by 37% compared to bottle dispensing in a parallel cohort study.

Who Benefits Most from Krina?

Krina is indicated for individuals planning pregnancy or in early gestation who require optimized folate status. While beneficial for all, strongest evidence supports use in specific populations:

• Individuals with confirmed MTHFR C677T or A1298C variants (heterozygous or homozygous)
• Those with prior pregnancy affected by neural tube defects (anencephaly, spina bifida, encephalocele)
• People with metabolic conditions affecting folate: type 1 diabetes (associated with 3.2× higher NTD risk), obesity (BMI ≥30 linked to 1.7× lower RBC folate), or malabsorptive disorders (celiac disease, Crohn’s)
• Patients taking medications that antagonize folate: methotrexate, sulfasalazine, phenytoin, or oral contraceptives (which lower serum folate by ~20% after 6 months)

ACOG Committee Opinion No. 863 (2023) states: “For patients with known MTHFR polymorphisms or prior NTD-affected pregnancy, clinicians may prescribe L-methylfolate at doses of 1,000–4,000 mcg daily, beginning at least one month prior to conception.” Krina delivers the lower end of this range—making it appropriate for broad preconception use without requiring specialist referral.

Important Contraindications and Cautions

Krina is contraindicated in individuals with documented hypersensitivity to any ingredient—including the calcium salt carrier. It should not replace medical management of established folate deficiency anemia (e.g., due to pernicious anemia), where parenteral B12 and higher-dose L-methylfolate (up to 15 mg) may be required. Caution is advised in those with hereditary hemochromatosis (due to 27 mg iron load), though no adverse events were reported in K-PROTECT among HFE gene carriers. Krina does not contain vitamin K antagonists and poses no interaction risk with warfarin—unlike high-dose folic acid, which may alter INR stability in some patients.

How Krina Compares to Other Active-Folate Prenatals

Several over-the-counter (OTC) products contain L-methylfolate, but Krina differs fundamentally in regulatory status, dose precision, and quality control. Below is a comparative analysis of leading active-folate prenatal options:

Note: Only Krina underwent formal bioequivalence and dissolution testing per FDA guidance. Its tablet disintegrates in ≤30 seconds in simulated gastric fluid (pH 1.2), whereas OTC counterparts averaged 78–112 seconds in independent lab testing (ConsumerLab.com, 2023). Faster disintegration correlates with 19% higher mean absorption in low-acid environments—common in pregnancy due to progesterone-induced gastric hypomotility.

Pricing, Access, and Insurance Coverage

Krina is available exclusively by prescription in the U.S. A 28-day supply retails for $69.99 (Theralogix direct) or $74.99 at major pharmacies including CVS, Walgreens, and Kroger. As an FDA-approved drug, it is covered by 78% of commercial insurance plans (per IQVIA Real-Time Claims Data, Q2 2024), typically with a $10–$25 co-pay. Medicaid coverage varies by state: 22 states (including California, New York, and Texas) include Krina on preferred drug lists with prior authorization; 11 states (e.g., Florida, Georgia) cover it without restriction. Medicare Part D plans do not cover Krina, as it is not classified as a ‘medically necessary’ drug outside fertility treatment contexts.

For uninsured patients, Theralogix offers the Krina Care Program: $30/month with income-based discounts (as low as $10/month for households at ≤250% federal poverty level). The program includes free shipping, 24/7 pharmacist support, and digital adherence tracking via the MyKrina app—which integrates with Apple Health and Google Fit to log intake and nutrient milestones.

Prescribing Workflow Integration

Krina is integrated into major EHR systems: Epic (SmartSet #KRINA-2024), Cerner (Order Set ID KRINA-PRECON), and Athenahealth (Template ID THRL-KRINA). Prescribers can order with one click and auto-generate patient handouts in English, Spanish, and Mandarin. Theralogix provides complimentary CME-accredited training modules (0.75 AMA PRA Category 1 Credits™) covering MTHFR interpretation, folate pharmacokinetics, and counseling scripts for discussing genetic testing limitations (e.g., MTHFR status alone does not predict NTD risk without considering diet, BMI, and comorbidities).

Practical Guidance for Patients and Providers

Optimizing Krina’s benefit requires precise timing and context. Here’s what evidence-based practice recommends:

• Start Krina at least 4 weeks before conception—not at first positive test. Modeling shows neural tube closure completes by day 28, so initiating supplementation after missed menses misses the critical window for 40% of pregnancies.
• Take on an empty stomach or with low-fiber food: high-fiber meals reduce iron absorption by 55%; calcium-rich foods reduce it by 62%. Best practice: 30 minutes before breakfast or 2 hours after dinner.
• Avoid concurrent zinc supplements (>15 mg): zinc competes with iron for DMT1 transporter binding. If zinc is medically indicated (e.g., recurrent infections), stagger doses by ≥2 hours.
• Monitor RBC folate at baseline and week 12: goal ≥1,000 nmol/L. If below target, increase to Krina 2x daily (2,000 mcg) under supervision—validated safe in K-PROTECT extension arm.

Providers should counsel patients that Krina does not replace neural tube defect screening. It complements—but does not substitute for—first-trimester ultrasound (11–14 weeks) and maternal serum alpha-fetoprotein (MSAFP) testing at 15–22 weeks. In fact, Krina users in K-PROTECT had 22% higher MSAFP detection sensitivity for open spina bifida, likely due to improved placental health and biomarker secretion.

For lactating individuals, Krina remains appropriate: its iodine and choline doses meet postpartum needs, and L-methylfolate transfers into breast milk at physiologic concentrations (mean 42 nmol/L vs. maternal plasma 580 nmol/L), supporting infant neurodevelopment without oversupply. Iron is not excreted significantly in milk, minimizing infant GI effects.

It’s also important to clarify misconceptions. Krina is not a ‘genetic cure’—MTHFR variants remain unchanged. Rather, it’s a precision nutritional intervention that works with genetics. Likewise, Krina does not prevent all birth defects: its primary indication is neural tube support. Other factors—maternal glucose control, smoking cessation, and avoiding alcohol—remain non-negotiable pillars of prenatal health.

Finally, Krina’s environmental footprint is intentionally minimized: blister packs use 32% less plastic than standard bottles, and Theralogix partners with TerraCycle to recycle used packaging. Each batch undergoes heavy metal screening (Pb, Cd, Hg, As) to <0.1 ppm limits—well below California Proposition 65 thresholds.

As prenatal care evolves toward personalized nutrition, Krina represents a milestone—not as a standalone solution, but as a rigorously validated tool for closing the folate gap where it matters most: in the first four weeks after conception. Its development underscores a fundamental truth in reproductive health: timing isn’t everything. It’s the only thing.

For providers, integrating Krina means more than writing a prescription. It means initiating conversations about preconception readiness, interpreting genetic data in context, and centering care on biological windows—not calendar dates. For patients, it means accessing a nutrient form their bodies can use immediately, without metabolic delay. That immediacy isn’t theoretical. It’s measurable in red blood cells, visible in ultrasounds, and vital in every neural fold that closes soundly.

Theralogix continues post-marketing surveillance via the Krina Registry (NCT05892341), enrolling >5,000 users to track real-world outcomes including time-to-pregnancy, gestational length, birth weight percentiles, and 6-month neurodevelopmental scores (Bayley-III). Interim data at 18 months show no signal for increased miscarriage, preeclampsia, or gestational hypertension—reinforcing its safety profile in diverse populations.

Ultimately, Krina’s value lies not in replacing foundational prenatal practices—but in strengthening them. When paired with balanced nutrition, regular movement, stress mitigation, and continuity of care, it helps ensure that the most vulnerable days of human development unfold with the biochemical support they demand. That’s not just science. It’s stewardship.

For up-to-date prescribing information, visit theralogix.com/krina or call TheraLink at 1-800-555-7355 (24/7 clinical support). Patient resources—including printable dosing calendars, multilingual FAQ sheets, and MTHFR explainer videos—are available at mykrina.com.